What insurance policy changes affect CPT 50593?

There are 8 tracked policy changes affecting CPT 50593, including updates from Humana, Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for CPT 50593?

Payers that have issued tracked updates for CPT 50593 include: Humana, Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when CPT 50593 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to CPT 50593. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for CPT 50593?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

50593 — A doctor uses freezing technique to destroy a kidney tumor through a needle inserted through the skin.: Insurance Policy Changes

50593 Insurance Policy Changes

CPT 50593, in plain terms, covers A doctor uses freezing technique to destroy a kidney tumor through a needle inserted through the skin. CPT 50593 is referenced in 8 tracked payer policy changes from Humana, Aetna, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 50593 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact

Cryoablation (CPB 0100, reviewed 2026-08-04)

Aetna·Effective Aug 4, 2026

Aetna has issued a comprehensive clinical policy bulletin (CPB 0100) establishing medical necessity criteria for cryoablation procedures across multiple anatomical sites and conditions. The policy clearly distinguishes between covered indications (e.g., renal masses up to 4cm, prostate cancer, atrial fibrillation, cervical dysplasia) and experimental/non-covered applications (e.g., breast carcinoma, benign prostatic hypertrophy, osteoarthritis). Billing teams must immediately implement these criteria as authorization rules to ensure claims are processed only when medical necessity requirements are met.

50593 Insurance Policy Changes

Ablation (Cancer and Noncancer Indications) - MEDICAID - FLORIDA (New)

Cryoablation (CPB 0100, reviewed 2026-08-04)

Cryoablation - Medicare Advantage (Revised)

Ablation (Cancer and Noncancer Indications) - MEDICAID - VIRGINIA (New)

Ablation (Cancer and Noncancer Indications) - MEDICAID - SOUTH CAROLINA (New)

Ablation (Cancer and Noncancer Indications) - MEDICAID - MICHIGAN (New)

Ablation (Cancer and Noncancer Indications) - MEDICAID - INDIANA (New)

Cryoablation of Tumors Located in the Kidney, Lung, Breast, Pancreas, or Bone